Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
Oruka Therapeutics (Nasdaq: ORKA), a clinical stage biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, will present at the Bank of America Securities 2025 Health Care Conference.
The presentation is scheduled for Tuesday, May 13th, 2025, at 3:55 PM PT. The company, based in Menlo Park, California, is working to establish new treatment standards in dermatology.
Oruka Therapeutics (Nasdaq: ORKA), una società biotecnologica in fase clinica specializzata nello sviluppo di nuovi biologici per malattie croniche della pelle, inclusa la psoriasi a placche, parteciperà alla Bank of America Securities 2025 Health Care Conference.
La presentazione è prevista per martedì 13 maggio 2025 alle 15:55 PT. L'azienda, con sede a Menlo Park, California, si impegna a definire nuovi standard di trattamento in dermatologia.
Oruka Therapeutics (Nasdaq: ORKA), una empresa biotecnológica en etapa clínica enfocada en desarrollar nuevos biológicos para enfermedades crónicas de la piel, incluida la psoriasis en placas, presentará en la Bank of America Securities 2025 Health Care Conference.
La presentación está programada para el martes 13 de mayo de 2025 a las 3:55 PM PT. La compañía, con sede en Menlo Park, California, trabaja para establecer nuevos estándares de tratamiento en dermatología.
Oruka Therapeutics (나스닥: ORKA)는 판상 건선을 포함한 만성 피부 질환을 위한 혁신적인 생물학적 제제 개발에 주력하는 임상 단계의 바이오테크 기업으로, Bank of America Securities 2025 Health Care Conference에서 발표할 예정입니다.
발표는 2025년 5월 13일 화요일 오후 3시 55분(태평양 시간)에 예정되어 있습니다. 캘리포니아 멘로파크에 본사를 둔 이 회사는 피부과 분야에서 새로운 치료 기준을 확립하기 위해 노력하고 있습니다.
Oruka Therapeutics (Nasdaq : ORKA), une société biotechnologique en phase clinique spécialisée dans le développement de nouveaux biologiques pour les maladies chroniques de la peau, y compris le psoriasis en plaques, présentera lors de la Bank of America Securities 2025 Health Care Conference.
La présentation est prévue pour le mardi 13 mai 2025 à 15h55, heure du Pacifique. La société, basée à Menlo Park, Californie, s'efforce d'établir de nouvelles normes de traitement en dermatologie.
Oruka Therapeutics (Nasdaq: ORKA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Biologika für chronische Hauterkrankungen einschließlich Plaque-Psoriasis spezialisiert hat, wird auf der Bank of America Securities 2025 Health Care Conference präsentieren.
Die Präsentation ist für Dienstag, den 13. Mai 2025, um 15:55 Uhr Pazifischer Zeit geplant. Das Unternehmen mit Sitz in Menlo Park, Kalifornien, arbeitet daran, neue Behandlungsstandards in der Dermatologie zu etablieren.
- Company is developing novel biologics for chronic skin diseases including plaque psoriasis
- Clinical stage status indicates progress in drug development pipeline
- Selected to present at a major healthcare conference, indicating industry recognition
- None.
MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, 2025, at 3:55 PM PT.
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
When is Oruka Therapeutics (ORKA) presenting at the Bank of America Healthcare Conference 2025?
What diseases does Oruka Therapeutics (ORKA) focus on treating?
Is Oruka Therapeutics (ORKA) a clinical stage biotech company?
Where is Oruka Therapeutics (ORKA) stock listed?
What type of medications is Oruka Therapeutics (ORKA) developing?
